Leerink initiated coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating and a price target of $12. The stock closed at $6.33 on Aug. 22.Read More
Roth Capital Partners raised its price target for “buy-rated Evotec AG (FSE:EVT) to €16 from €5.50, reflecting a review of the company’s partnered pipeline assets. The stock was recently quoted at €11.66.Read More
Profound Medical (OTCQX:PRFMF; TSXV:PRN) has agreed to expand an existing collaboration with Royal Philips (NYSE:PHG; AEX:PHIA) and acquire Philips’ Sonalleve MR-HIFU business, establishing Profound as a market leader in magnetic resonance (MR) ultrasound ablation therapy.Read More
Dr. Sabine Mai, a co-founder and principle inventor of 3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0), will present on Feb. 21 at the International Molecular Medicine Tri-Conference in San Francisco, results of a prospective blood-based prostate cancer pilot study using the company’s TeloView software platform.Read More
After an end-of-Phase 2 meeting with the FDA, Aurinia Pharmaceuticals (NASDAQ:AUPH) plans to begin a single Phase 3 clinical trial for voclosporin in the treatment of lupus nephritis (LN).
Aurinia believes the Phase 3 trial, whose design is consistent with the ongoing AURA study, will support a NDA submission.Read More
Results of Mesoblast’s (NASDAQ:MESO; ASX:MSB) Phase 2 trial of its allogeneic mesenchymal precursor cell (MPC) product candidate, MPC-300-IV, in patients with diabetic kidney disease have been published in the current issue of the peer-reviewed journal, EBioMedicine.
The paper concluded that a single intravenous infusion of MPC-300-IV was well tolerated and had positive effects on renal function at the 12-week primary endpoint in the trial with adult patients with Type 2 diabetic nephropathy.Read More
Knight Therapeutics (TSX:GUD) has closed on a $1-million equity investment in closely-held 3D Signatures, which has completed a business combination and public listing transaction.
3D is a personalized medicine company, with a proprietary software platform based on the three-dimensional analysis of telomere organization. The technology is supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease.Read More
Anavex Life Sciences (NASDAQ:AVXL) announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73 Phase 2a study in mild-to-moderate Alzheimer’s patients at the Alzheimer’s Association International Conference in Toronto.Read More
Viking Therapeutics (NASDAQ:VKTX) announced positive top-line results from a proof-of-concept study of VK0214 in a mouse model of X-linked adrenoleukodystrophy (X-ALD).
The results showed that VK0214 rapidly reduced very long chain fatty acid (VLCFA) levels in plasma by more than 25% in treated animals, compared with vehicle controls. The study successfully achieved its primary objective, which was to demonstrate the ability of VK0214 to lower plasma VLCFA levels after six weeks of treatment.Read More
ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein TDP43, which is implicated in the development of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
“ProMIS will apply its proprietary computational algorithms, supplemented by other methods pioneered by ProMIS scientists, to identify specific therapeutic targets on misfolded TDP43,” SCO, Dr. Neil Cashman, said in a statement.Read More
Stifel launched coverage of Selecta Biosciences (NASDAQ:SELB) with a “buy” rating and $23 price target. The stock closed at $14 on Friday.
“Selecta’s SVP-Rapamycin technology has the potential to open the doors of immunological tolerance and allow patients to be treated with recombinant protein ‘creations’ designed to combat disease,” writes analyst Thomas Shrader.Read More
The Massachusetts Life Sciences Center (MLSC), Massachusetts General Hospital (MGH) and five leading BioPharma companies have launched the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS) to find therapies for Alzheimer’s disease.
The new center will be located at MGH. Industry partners, including AbbVie, Biogen, Janssen Pharmaceuticals, Merck and Sunovion Pharmaceuticals, have committed $1.25-million in Alzheimer’s-related research funding.Read More
Stifel Research launched coverage of Voyager Therapeutics (NASDAQ:VYGR) with a “buy” rating and 12-month price target of $33. The stock closed at $11.81 on Thursday.
Voyager is a clinical stage-gene therapy company with the potential to be the market leader in design, development and commercialization of gene products focused on diseases of the central nervous system (CNS), writes analyst Katherine Breedis.Read More
ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta (Ab), are implicated in the development of Alzheimer’s disease (AD).
“With multiple product candidates in our Ab program progressing to final validation and selection for drug development, we are focusing our science team and discovery processes on the other half of the root cause – tau prions.” SCO, Dr. Neil Cashman, explained in a statement.Read More
The FDA has granted orphan drug designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX 2-73 for the treatment of Rett syndrome.
In a statement, Christopher Missling, president and CEO, said orphan drug designation marks the first U.S. movement for ANAVEX 2-73.Read More
Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday.
LabStyle is an emerging digital health company focused on the monitoring and management of diabetes.Read More